autologous whole tumor cell vaccine

The **autologous whole tumor cell vaccine** is an experimental, patient-specific cancer immunotherapy developed by **Leiden University Medical Center** for the treatment of metastatic melanoma. This biologic therapy consists of irradiated autologous (patient-derived) whole melanoma tumor cells. By utilizing the patient's own tumor cells, the vaccine presents a broad spectrum of tumor-associated antigens to the immune system, aiming to prime and expand tumor-reactive T cells. In clinical research, it has been evaluated as part of a combination regimen that includes the adoptive transfer of melanoma-reactive T cells and low-dose interferon-alpha to enhance the anti-tumor immune response.

Other names

irradiated autologous whole tumor cell vaccineautologous melanoma cell vaccine